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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol national units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In September 2016, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly 
known as acryloylfentanyl, through a joint assessment based 
upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on acryloylfentanyl satisfied criteria 4 and 6. The two 
agencies therefore concluded that sufficient information had 
been accumulated to merit the production of a Joint Report on 
acryloylfentanyl as stipulated by Article 5.1 of the Council 
Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, 
on 7 September 2016 the EMCDDA and Europol launched 
a procedure for the collection of information on 
acryloylfentanyl, in order to prepare the Joint Report. The 
information was collected mainly through the Reitox National 
Focal Points in the Member States, Turkey and Norway as well 
as the Europol National Units. In addition, the EMA collected 
information through the national competent authorities 
responsible for human and veterinary medicinal products in 
the Member States as well as in Norway, Iceland and 
Liechtenstein. The EMA also provided information as relevant 
to the centralised procedure for authorising medicinal 
products. The information collection process was largely 
concluded by 19 October 2016; additional information and 
(1) OJ L 127, 20.5.2005, p. 32. 
clarifications from some countries were received the following 
day after the deadline.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of acryloylfentanyl in their country;
 ¡ the level of distribution of acryloylfentanyl in their country;
 ¡ the level of trafficking of acryloylfentanyl in their country, 
both for internal, transit or export purposes;
 ¡ the number of seizures of acryloylfentanyl in their country, 
the total amount of the seizures, country of origin, details 
on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, in the 
production, distribution and trafficking of acryloylfentanyl in 
their country; and,
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of acryloylfentanyl.
Europol received responses from 20 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland, and Liechtenstein, provide 
information on whether:
 ¡ the new psychoactive substance acryloylfentanyl has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance acryloylfentanyl is the 
subject of an application for a marketing authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance acryloylfentanyl has 
been suspended.
Twenty-five countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Cyprus, Czech Republic, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, 
Luxembourg, Poland, Portugal, Slovenia, Spain, Sweden and United Kingdom.
(3) Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, 
Greece, Iceland, Ireland, Italy, Malta, Netherlands, Norway, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom provided a response 
in relation to human and veterinary medicinal products. Croatia and Hungary 
provided a response in relation to human medicinal products. France and Latvia 
provided a response in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
acryloylfentanyl is used to manufacture a medicinal product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-five countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
1. a structured questionnaire to the Reitox National Focal 
Points. The EMCDDA received replies from all 28 Member 
States, as well as Turkey and Norway;
2. reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
3. routine monitoring of open source information;
4. a specific information request to the World Health 
Organization on whether or not acryloylfentanyl is under 
assessment by the United Nations system; and,
5. a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’), and, online vendors 
selling acryloylfentanyl.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part) (5). The information 
included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was 
provided by the EMA. Images of the seizures and collected 
samples reported to the EMCDDA and Europol are provided in 
Annex 1 and Annex 2.
(4) Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, Germany, 
Greece, Iceland, Ireland, Italy, Malta, Netherlands, Norway, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom provided a response 
in relation to human and veterinary medicinal products. Croatia and Hungary 
provided a response in relation to human medicinal products. France and Latvia 
provided a response in relation to veterinary medicinal products.
(5) The sections on chemistry, pharmacology and toxicology, dependence 
liability and abuse potential, and characteristics of users were produced based 
on a technical report prepared by Dr István Ujváry, under EMCDDA contract 
CT.16.SAT.0099.1.0.
  3.  Information required by Article 5.2 
of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1.  Chemical and physical description, including the 
names under which the new psychoactive 
substance is known (Article 5.2(a) of the Council 
Decision)
Chemical description and names
Acryloylfentanyl belongs to the 4-anilidopiperidine class of 
synthetic opioids. This class also includes fentanyl and 
acetylfentanyl (6), which are internationally controlled (7).
Acryloylfentanyl differs from fentanyl in the double bond 
present in the 2-position of the propane attached to the 
N-phenyl moiety and is therefore an unsaturated analogue of 
fentanyl.
The molecular structure, molecular formula, and molecular 
mass of acryloylfentanyl are provided in in Figure 1.
The synthesis and antinociceptive activity of acryloylfentanyl 
were first described in 1981 (Zhu et al., 1981).
Commonly used names: acryloylfentanyl or acrylfentanyl
Systematic (IUPAC) name: N-phenyl-N-[1-(2-phenylethyl)
piperidin-4-yl]prop-2-enamide
Chemical Abstracts names: N-phenyl-N-[1-(2-phenylethyl)-4-
piperidinyl-2-propenamide
Other chemical names: N-(1-phenethylpiperidin-4-yl)-N-
acroylanilinopiperidine; N-(1-phenylethylpiperidin-4-yl)-N-
phenylacrylamide
Other names and code names: ‘akrylfentanyl’ (Swedish), 
acryloyl-F, Acr-F, ACF (8)
(6) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. 
(7) Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs.
(8) Important not to confuse ‘ACF’ with ‘AF’, which is one of the street names for 
acetylfentanyl.
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Chemical Abstracts Service (CAS) registry numbers (9):
82003-75-6:  free amine
79279-03-1:  hydrochloride salt
IUPAC International Chemical Identifier Key (InCHI Key) (10):
RFQNLMWUIJJEQF-UHFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
results.
Physical description
Acryloylfentanyl contains one basic nitrogen atom in the 
piperidine ring which can readily form salts with organic or 
inorganic acids.
There is no solubility data on acryloylfentanyl or its 
hydrochloride salt; due to its close similarity to fentanyl, the 
free base is expected to be sparingly soluble in water; the 
hydrochloride and citrate salt are expected to have improved 
aqueous solubility.
Acryloylfentanyl is expected to be highly lipophilic. Therefore, 
carry-over of traces of the substance during sample handling 
and analysis can be problematic (Degg, 2014).
Acryloylfentanyl has been typically seized in liquid or in tablet 
form. It has also been detected in powder form, and, in 
(9) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(10) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
a capsule in one case. A more detailed description of seizures 
and collected samples can be found in section 3.2.1 and 
section 3.2.2.
Detection and analysis
Gas Chromatography – Mass Spectrometry (GC-MS), Fourier 
Transform Infrared Spectroscopy (FT-IR) and Nuclear 
Magnetic Resonance (NMR) are available in the literature 
(Breindahl et al., 2016; Essawi, 1999; Slovenian National 
Forensic Laboratory, 2016).
Difficulties may be encountered in the analytical detection of 
acryloylfentanyl. Due to its close structural similarity with 
fentanyl, it is possible that immunoassays for fentanyl do not 
distinguish between the two compounds (Breindahl et al., 
2016). Similarly, acryloylfentanyl is not expected give 
a response to tests developed for morphine-type opioids. 
There is no information on the reaction of acryloylfentanyl to 
presumptive colour tests.
 3.2.  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on 
the means and methods of manufacture of the 
new psychoactive substance (Article 5.2(b) of 
the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
FIGURE 1
Molecular structure, molecular formula, and molecular mass of acryloylfentanyl. Information on fentanyl is provided for 
comparison.
acryloylfentanyl fentanyl
Molecular formula C
22
H
26
N
2
O C
22
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28
N
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Molecular mass 334.46 336.48
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3.2.1 Information provided to Europol
Europol received replies from 20 Member States (Austria, 
Belgium, Cyprus, Czech Republic, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Latvia, Lithuania, 
Luxembourg, Poland, Portugal, Slovenia, Spain, Sweden and 
United Kingdom).
The majority of countries who provided information to Europol 
reported that they have no available information on 
acryloylfentanyl. Since laboratory detection of this opioid is 
particularly challenging, the substance may not always be 
identified. For example, Belgium reported no detections of 
acryloylfentanyl but highlighted that, due to difficulties in 
forensic identification, it doesn’t rule out the potential 
presence of the substance on the Belgian market.
Three countries provided information on acryloylfentanyl 
(Estonia, Finland and Sweden).
The level of production
No information was received in relation to the production of 
acryloylfentanyl. Estonia and Sweden informed Europol that 
acryloylfentanyl was ordered in powder form from China. 
According to information from Swedish authorities, the 
substance is then further handled by those involved in selling 
acryloylfentanyl, with the powder being used to make 
solutions. Those solutions are then placed into unmarked 
spray bottles of different colours, which are also sourced in 
China (see photos in Annex 2).
The level of distribution
Seizures were reported by 3 countries (Estonia, Finland and 
Sweden).
Estonia
Estonia reported 9 seizures of acryloylfentanyl (between June 
and 15 September 2016). All seizures were powders, with 
amounts ranging from 0.14 to 24.89 grams. The source of 
acryloylfentanyl seized in Estonia was reported as China. The 
substance was mainly purchased via the Internet and then 
either posted directly to Estonia or routed through other 
countries (for example Latvia).
Estonian authorities stated that the substance is consumed 
primarily by injection and that the use of nasal sprays has not 
been reported.
One death case was identified, which could be associated 
with acryloylfentanyl (11).
(11) This case has not been reported to the EMCDDA.
Finland
Finland reported 1 seizure of several tablets containing 
acryloylfentanyl, which occurred in August 2016 (see photos 
in Annex 1).
Due to the nationality of the suspects involved in the seizure 
case and the geographic location where it took place (Åland 
Islands), Sweden was reported as the possible source for the 
seized tablets.
Sweden
Sweden reported that acryloylfentanyl was the most common 
fentanyl derivative for sale on the domestic illicit market from 
the end of January to September 2016, after which time it 
became scheduled as narcotic.
Nasal sprays containing various fentanyl derivatives were 
commonly sold on the surface internet from late 2015 
onwards, most of which reportedly contained acryloylfentanyl.
Swedish authorities reported 36 fatalities to Europol 
associated with acryloylfentanyl, four of which are still under 
investigation.
In 2016, the Swedish authorities have seized an amount of 
9.52 grams, 1595 mL and 856.5 units of acryloylfentanyl as 
liquids or tablets.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures mentioned above.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from all 28 Member States, 
as well as from Turkey and Norway. Of these, six Member 
States (Denmark, Estonia, Finland, Latvia, Slovenia and 
Sweden) reported detections of acryloylfentanyl (12). Images 
of the seizures and collected samples reported to the 
EMCDDA are provided in Annex 1.
It should be noted that the number of detections of 
acryloylfentanyl may be underestimated since the substance 
is not routinely screened for. Only two Member States (Finland 
in Sweden) reported that acryloylfentanyl is part of routine 
(12) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
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screening (13). The availability of a reference standard was not 
mentioned by any of the countries.
Seizures
In total, 95 seizures (14) have been reported to the EMCDDA by 
five Member States: Denmark (1 seizure), Estonia (9), Finland 
(1), Latvia (2), and Sweden (82). All the seizures were made in 
2016 by Police or Customs. Most seizures have been made at 
street-level. Two seizures were made at a scene of death and 1 
seizure was made in prison from incoming mail.
These seizures included:
 ¡ 49 seizures of liquids, all made in Sweden, amounting to 
a total of 1494 mL;
 ¡ 27 seizures of tablets (Sweden and Finland) amounting to 
896 tablets. One of these seizures (99 blue oval tablets 
with no logos or markings seized in Finland), may be linked 
to a death.
 ¡ 18 seizures of powder amounting to 66.19 grams (Estonia, 
Latvia and Sweden). In Latvia, one of the seizures was 
made at a scene of death. Another seizure was made in 
prison from incoming mail (a package with light beige 
powder which was found inside a tube for cosmetic cream).
 ¡ 1 capsule, also containing triethylamine, seized in Denmark.
No quantitative information on purity was provided to the 
EMCDDA.
The capsule seized in Denmark contained acryloylfentanyl and 
triethylamine and some of the powders seized in Estonia 
contained acryloylfentanyl and sugars. For the remaining 
seizures, there is no information on whether other substances 
were also detected.
Collected samples
Slovenia reported a sample of light green powder which was 
purchased from the Internet. The sample, received in May 
2016, was shipped from China.
Biological samples
A total of 47 detections where acryloylfentanyl was 
analytically confirmed in biological samples were reported by 
two Member States: Denmark (1 sample) and Sweden (46).
(13) Information provided by the Member States, Turkey and Norway to the 
EMCDDA. 
(14) Many ‘seizures’ relate to individual cases, however, some data provided to the 
EMCDDA are aggregated at the country level. Data is drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU 
EWS Progress Reports and Final Reports) and from individual EMCDDA–Europol 
Reporting forms submitted to the EMCDDA on an ad hoc basis.
These related to:
 ¡ 40 serious adverse events, all of them deaths, reported by 
Denmark (1) and Sweden (39) (see section 3.4.1);
 ¡ 6 cases related either to patients undergoing drug 
treatment (3) or cases related to persons suspected of 
having consumed drugs, committed minor offences, or 
crimes (3); and,
 ¡ 1 case of a person suspected of driving under the influence 
of drugs.
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the 
new psychoactive substance (Article 5.2(c) of 
the Council Decision)
No information concerning organised crime involvement in the 
manufacture and/or trafficking of the acryloylfentanyl was 
provided by any of EU Member States.
Sweden reported that there are individuals involved in the 
illegal trade of acryloylfentanyl. Of these, two known vendors 
are linked to organised crime groups.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
acryloylfentanyl.
In Sweden, online sales of fentanyl and its derivatives are 
reported to generate large profits. Acryloylfentanyl is sold on 
several Swedish websites on the surface internet.
Two Swedish websites where acryloylfentanyl has been sold, 
‘thesmack.biz’ and ‘RC24’, had sales of 7 and 15 million 
Swedish Krona (SEK) respectively in 2015.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of acryloylfentanyl.
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 3.4.  A first indication of the risks associated with the 
new psychoactive substance, including the 
health and social risks, and of the characteristics 
of users — Article 5.2(d) of the Council Decision 
3.4.1 Serious adverse events reported to the EMCDDA
Information about 63 serious adverse events (15) associated 
with acryloylfentanyl was reported to the EMCDDA by 4 
Member States (Denmark, Finland, Latvia and Sweden). These 
cases comprised 21 acute intoxications and 42 deaths. An 
overview of these data is presented below.
Acute intoxications
Information about 21 acute intoxications associated with 
acryloylfentanyl was reported by Sweden. All the cases 
presented to hospital emergency departments. Information on 
whether acryloylfentanyl was analytically confirmed was not 
reported in any of the cases. The identification of the cases 
reported as non-fatal intoxications was made by the Swedish 
National Poisons Information Centre based on calls made to 
the centre. All the cases occurred between March and August 
2016. 10 of the 21 cases were classified as non-fatal 
intoxications; in the remaining 11 cases the outcome of the 
intoxication was unknown.
Demographics
18 of the acute intoxications were male; 3 were female. For 
the cases for which the age was known, the ages ranged from 
22 to 51 years old. The age was not known for 11 of the male 
patients. The mean age of the male cases for which an age 
was known was 35 years (median 29); the mean age for the 
female cases was 28 years (median 22).
Substances analytically identified
No analytical information is available regarding biological 
samples taken from the patients. The Poisons Information 
Centre has reported that in 6 cases there were indications 
that the patient may have ingested a substance other than 
acryloylfentanyl. Stimulants were reportedly taken in 4 out of 
the 6 cases (4-methylphenidate, the cathinones 4-Cl-α-PPP 
and N-ethylhexedrone, and amphetamine); in two cases the 
cathinones were injected. Opioids were reported in 1 case 
(oxycodone with buprenorphine). Benzodiazepines were 
registered in 2 cases.
(15) Serious adverse event means any adverse event, whether analytically 
confirmed or not, that is associated with the consumption of a new psychoactive 
substance in a human that: results in death; is life-threatening; requires intensive 
treatment in an emergency room and/or requires hospitalisation; results 
in persistent or significant disability or incapacity; results in substance 
dependency or substance abuse; consists of a congenital anomaly or birth 
defect; or is an important medical event that may not be immediately life-
threatening or result in death or hospitalisation but may jeopardise the patient or 
may require intervention to prevent one of the other outcomes listed above. 
Examples of such events are: convulsions that do not result in hospitalisation.
It is important to note that this information is based on self 
reports rather than analytical results derived from physical 
samples.
Clinical features
Data on the clinical features (16) related to the 21 acute 
intoxications were generally consistent with opioid toxicity (in 
particular the opioid overdose triad). Other symptoms were 
reported, albeit less frequently.
Clinical features were reported for 19 out of 21 cases and no 
symptoms were reported in the remaining 2 cases. Reported 
symptoms included: unconsciousness (10 cases), respiratory 
depression (6), miosis (3), vomiting/nausea (3), tachycardia 
(17) (3), restlessness/anxiety (3), low oxygen saturation (2), 
dizziness (2) and hypertension (2). Features reported only 
once included: cyanosis, blurred vision, constipation, 
somnolence, tiredness, high body temperature (18), chest 
pain (18), hallucinations, muscular symptoms.
Naloxone was administered in 8 cases. In 4 of these cases, the 
patient was unconscious prior to administration, after which 
he/she woke up.
Seriousness and outcome
All cases required treatment in hospital. In 13 of the 21 cases, 
the seriousness of the intoxication was classified as life-
threatening; the remaining cases were classified as not 
life-threatening.
In respect to the outcome of the intoxication:
 ¡ In 10 cases the patients were reported to have recovered; 
and,
 ¡ In 11 cases the outcome was unknown.
Route of administration
The route of administration was reported for 17 out of 21 
cases. In 10 cases (58.8%) acryloylfentanyl was taken nasally 
using a nasal solution; in 3 cases (17.6%) it was taken orally or 
‘probably orally’ as tablets; in 2 cases (11.8%) it was snorted 
(as a powder or presumably crushed tablets); in 1 case it was 
probably taken ‘orally and snorted’ (5.9%) using tablets and 
lastly in 1 case (5.9%) it was injected (as a nasal solution).
Name of the substance/product used
In all 21 cases reported to the Poisons Information Centre, the 
patient was reported to have taken ‘akrylfentanyl’, the Swedish 
name for acryloylfentanyl.
(16) Includes an abnormal laboratory finding. 
(17) In all 3 cases, the patient was reported to have also taken a stimulant.
(18) In this case, the patient was reported to have also taken a stimulant.
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Source of the substance
Information on where the patients had sourced the substance 
was available in 4 cases: in all of them acryloylfentanyl was 
sourced from the internet.
Physical form
Information on the physical form of acryloylfentanyl used by 
the patients was available in 19 cases: 12 of them (63%) used 
a nasal solution; 5 of them used tablets (26%), 1 of them (5%) 
used a powder, and the remaining case was reported to have 
used both a nasal solution and tablets.
Amount or dose administered
The amount of acryloylfentanyl used by the patients was 
reported in 10 cases.
 ¡ In 5 cases, where the route of administration was nasal, the 
dose varied between 1 mg to 40 mg. The dosage regimen 
(19) was not clear in all cases. In 2 cases the patient had 
been taking 20 mg/day; in another case the patient took 
5-6 doses of 0.2 mg (time period not specified); in another 
case the patient took 4 doses of 10 mg (time period not 
specified).
 ¡ In 2 cases, where the route of administration was oral or 
‘probably oral’, the doses reported were 0.3 mg (1/2 tablet) 
and 3.00 to 3.75 mg (4 or 5 tablets). The time period in 
which these doses were taken was not specified.
 ¡ In 2 cases, where the route of administration was snorting, 
the doses reported were 9 mg (15 tablets containing 0.6 
mg of acryloylfentanyl) and 40 mg. The time period in which 
these doses were taken was not specified.
 ¡ In 1 case, where the route of administration was not known, 
the dose taken by the patient was 68 mg of 
acryloylfentanyl. The time period in which this dose was 
taken was not specified.
As mentioned above, it is important to note that 
acryloylfentanyl was not analytically confirmed from biological 
or physical samples taken from the patients and therefore 
these data should be taken as indicative only. Furthermore, 
quantities in the milligram scale are inherently prone to errors.
Analysis of the concentration of nasal spray solutions of 
acryloylfentanyl in Sweden suggests that a standard 10 mL 
spray bottle can usually contain 20 mg substance. A 10 mL 
bottle is deemed to be enough for 100 sprays (i.e. 0.2 mg/
spray) (Helander, personal communication, October 2016).
(19) In this context, the ‘dosage regimen’ should be understood as the schedule of 
doses of acryloylfentanyl per unit of time.
Deaths
Information about 42 deaths associated with acryloylfentanyl 
was reported by four Member States: Denmark (1 case), 
Finland (1), Latvia (1) and Sweden (39). Acryloylfentanyl was 
analytically confirmed from biological samples taken from the 
decedents in 40 cases. In the remaining 2 cases, identification 
was made based on samples recovered from the scene of 
death (epidemiologically linked samples).
The discussion that follows will focus on the cases for which 
analytical confirmation from biological samples was obtained. 
These were: Denmark (1 case) and Sweden (39 cases).
Demographics
Of the 40 deaths, 34 were male (85%) and 6 were female 
(15%). The age of the decedents ranged from 19 to 54 years 
old. The mean age of the male decedents was 31 years 
(median 29.5); the mean age of the female decedents was 
42 years (median 43).
Number of deaths by year
All deaths occurred in 2016 (April to September). Overall, 
32 of the deaths (80%) occurred in the 3 summer months 
(June to August 2016), with 13 (32.5%) deaths taking place in 
August 2016.
Cause of death
The cause of death was reported in 33 cases. For the 
remaining 7 cases the cause of death was unknown at the 
time of reporting to the EMCDDA.
In 29 (88%) of the 33 cases where the cause of death was 
reported, acryloylfentanyl was either reported as the cause of 
death (24 cases) or as a contributing factor (5); in the 
remaining 4 cases an alternative cause of death was reported 
(‘intoxication with narcotics’; ‘intoxication with drugs (drug 
abuse)’; ‘drug addiction’ and ‘suicide with several substances’).
In 2 deaths acryloylfentanyl was the only substance detected; 
in both these cases acryloylfentanyl was reported as the 
cause of death. Other substances were detected in the 
remaining 38 deaths. These included: benzodiazepines and 
their metabolites, antidepressants, alcohol, antipsychotics, 
‘Z’-drugs, pregabalin and, to a lesser extent THC, cathinones, 
synthetic cannabinoids, amphetamine, MDMA, gabapentin. 
Opioids (including oxycodone and buprenorphine) were found 
in 3 out of 38 cases.
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Route of administration
The route of administration was known for 1 of the 40 deaths: 
in that case acryloylfentanyl was snorted.
Source
Information on where the decedents had sourced the 
substance was available in 1 case, in which the substance 
was obtained via an acquaintance.
Amount or dose administered
No information was reported on the amount of substance 
administered by the decedents.
3.4.2  Serious adverse events identified in open 
source information
No publications were found in open source information 
regarding fatal or non-fatal intoxications associated with 
analytically confirmed acryloylfentanyl.
3.4.3 Pharmacology
Overview
Published data on the pharmacology of acryloylfentanyl are 
limited to non-clinical studies. In vitro and animal studies 
establish acryloylfentanyl as a potent and long-lasting 
antinociceptive agent acting on the opioid system.
The antinociceptive activity of acryloylfentanyl is blocked by 
the opioid antagonist naloxone though this protective effect is 
transient. The acute toxicity of acryloylfentanyl has not been 
determined but based on observations during a mouse-study, 
it appears to be similar to that of fentanyl.
Further research is required in order to have a more detailed 
understanding of the mode and mechanism of action of 
acryloylfentanyl, including its abuse liability and dependence 
potential, and how this relates to humans. This should also 
include study of the pharmacological effects of the 
metabolites of acryloylfentanyl.
Pharmacodynamics
In vivo data
There has been one single study in the scientific literature 
focusing on the binding of acryloylfentanyl to the opioid 
receptor. Maryanoff et al. (1982) determined the binding 
affinities of a series of compounds, including acryloylfentanyl, 
designed as potential covalent receptor affinity labels using 
a rat brain preparation and tritiated naloxone or naltrexone as 
competing opioid receptor ligands. Morphine, fentanyl and 
(+)-3-methylfentanyl were used as comparative standards.
TABLE 1
Opioid receptor binding data for morphine, fentanyl and 
its analogues (Maryanoff et al., 1982). The receptor 
affinity is expressed by IC
50
 values representing the 
concentration required for displacement of 50% of tritiated 
naloxone or naltrexone radioligands in a competition assay 
using rat brain homogenates.
Compound
IC
50
 (nM)
[3H]naloxone [3H]naltrexone
morphine 4.2 27
fentanyl 1.6 25
acryloylfentanyl 1.4 17
(+)-3-methylfentanyl 0.6 1.3
As seen in Table 1, the IC
50
 values obtained for fentanyl and 
acryloylfentanyl were comparable; morphine was somewhat 
less effective in inhibiting the binding of radiolabeled receptor 
antagonists.
The results of this study indicate that the opioid receptor 
affinity of acryloylfentanyl is similar to that of fentanyl and 
somewhat higher than that of morphine, at least in this 
particular rat brain preparation. Laboratory experiments failed 
to find evidence for irreversible binding of acryloylfentanyl to 
opioid receptors.
Search in the PubChem Substance database for biological 
activity of acryloylfentanyl found 28 test results deposited 
yet the substance was found inactive in all assays that 
included a range of non-opioid related targets (NCBI 
PubChem, 2012)(20).
Animal studies
There have been two studies investigating the antinociceptive 
activity of acryloylfentanyl in the mouse (Zhu et al., 1981; 
Maryanoff et al., 1982).
The first publication mentioning acryloylfentanyl describes an 
extensive structure–activity relationship study involved 22 
fentanyl analogues, and morphine and fentanyl as 
comparative standards (Zhu et al., 1981). The antinociceptive 
activities of morphine, fentanyl and acryloylfentanyl in mice 
upon intraperitoneal administration are shown in Table 2.
As seen in Table 2, in this rodent model of analgesia 
acryloylfentanyl is about 170-times more effective as an 
antinociceptive agent than morphine though somewhat less 
potent than fentanyl.
(20) Available at: https://pubchem.ncbi.nlm.nih.gov/substance/144091883 
(accessed: 6 October 2016).
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TABLE 2
Antinociceptive activity of morphine, fentanyl and 
acryloylfentanyl in mice upon intraperitoneal administration 
(Zhu et al., 1981). The antinociceptive activity was assessed 
by the hot-plate test (55 ºC) measuring the latency of 
nociception.
Compound
ED
50
(21)
(mg/kg)
Potency ratio
to morphine
Potency ratio
to fentanyl
morphine 13.9 1 0.0045
fentanyl 0.062 224 1
acryloylfentanyl 0.082 169.5 0.76
Essawi (Essawi, 1999) studied five fentanyl analogues, 
including acryloylfentanyl, as potential receptor affinity labels 
and antinociceptive agents in the mouse using the hot-plate 
assay; morphine and fentanyl were comparative standards. 
Upon intraperitoneal administration at doses below 1 mg/kg, 
acryloylfentanyl was a more potent antinociceptive agent than 
fentanyl: while the effect of fentanyl at 0.1, 0.2 and 0.5 mg/kg 
dropped considerably at 60–70 min and became insignificant 
at 90–100 min after treatment; ‘at comparable doses, 
acryloylfentanyl maintained considerable analgesia at 90 and 
120 min after administration. In its duration, the time-
response profile of acryloylfentanyl resembled more closely 
that of morphine (20 mg/kg) than that of fentanyl’.
At 6.8 mg/kg and 17 mg/kg doses the antinociceptive effect 
of acryloylfentanyl was sustained for up to 4.5 hours without 
signs of opioid toxicity. At the 25 mg/kg dose, motor activity 
was inhibited, but the ‘animals were not cataleptic and 
returned to continuous circling behaviour 3.5 hours after 
treatment’. However, at a dose of 50 mg/kg convulsions 
developed after 1 hour and ‘60% lethality was observed from 
apparent respiratory depression’.
Pre-administration by 30 min of 2 mg/kg naloxone blocked 
the antinociceptive effect of 0.85 mg/kg acryloylfentanyl for 
about 40 min when this antagonist effect disappeared and 
analgesia and other morphine-like effects could be noted for 
about 50 min.
(21) The median effective dose (ED
50
) can be calculated by measuring the 
prolongation of latency times of a response to pain after administration of the 
test substance at various doses as compared to untreated control.
Similar transient antagonist effect was observed when 
naloxone (2 mg/kg) was administered 40 min after 
acryloylfentanyl-treatment (0.85 mg/kg): the reversal of the 
antinociceptive effect lasted for 70 min, and then 
antinociception returned to the same level as before naloxone 
administration. It was concluded that acryloylfentanyl “has 
a mode of interaction with receptors different from morphine”. 
Of the other three substances, the crotonoyl analogue only 
was slightly active.
Pharmacokinetics
Due to its lipophilicity, acryloylfentanyl (like fentanyl) is 
expected to readily cross the blood–brain barrier and also 
diffuse into fat and other tissues (i.e., it is expected to have 
a large volume of distribution).
No preclinical or human clinical studies were identified which 
focus on the pharmacokinetics, including metabolism, of 
acryloylfentanyl.
Based on structural and pharmacological similarity with 
fentanyl, acryloylfentanyl may be present in biological 
matrices mainly as its ‘desphenethyl’ derivative: ‘acryloyl 
norfentanyl’ (22).
A phenolic metabolite of acryloylfentanyl (23), if formed, may 
have some level of opioid activity and thus may contribute to 
the biological, including toxicological, properties of the parent 
substance.
Abuse liability and dependence potential
There are no data available from clinical studies on the 
dependence potential of acryloylfentanyl.
Limited information from self-reported user experiences on 
drug user websites indicates abuse potential and the 
development of tolerance.
(22) Systematic name: N-phenyl-N-(piperidin-4-yl)prop-2-enamide. Molecular 
weight: 230.30
(23) Systematic name: N-{1-[2-(4-hydroxyphenyl)ethyl]piperidin-4-yl}-N-
phenylprop-2-enamide.
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3.4.4 Toxicology
Animal data
There is limited information on the acute toxicity of 
acryloylfentanyl. In the mouse, the intraperitoneal injection of 
25 mg/kg of the drug caused a transient suppression of motor 
activity; however, a dose of 50 mg/kg produced convulsions 1 
hour after drug administration and ‘60% lethality was observed 
from apparent respiratory depression’ (Essawi, 1999). From 
these data, an acute mouse LD50 value between 25 and 50 
mg/kg upon intraperitoneal administration may be postulated. 
While no comparative standard was used in this particular 
study, other sources on fentanyl indicate that the acute toxicity 
of acryloylfentanyl is similar to that of fentanyl (24).
There are no reports on the chronic toxicity of acryloylfentanyl.
Human data
There have been no studies on the human toxicity of 
acryloylfentanyl. However, the comparable pharmacology of 
acryloylfentanyl and fentanyl in preclinical studies both in vitro 
and in vivo suggests toxicological similarity. For fentanyl, the 
estimated human lethal dose could be as low as 2 mg when 
injected (Marquardt et al., 1995; Baselt, 2000; Reeves and 
Ginifer, 2002; Moffat et al., 2011).
Data from serious adverse events associated with 
acryloylfentanyl are discussed above (Section 3.4.1). Based on 
limited data, it appears that the toxidrome of acryloylfentanyl 
may be broadly similar to other fentanyls and narcotic-
analgesic opioids. This includes the opioid overdose triad of 
miosis, unconsciousness, and respiratory depression.
3.4.5 Characteristics of users
Data on the characteristics of users of acryloylfentanyl is 
limited to information derived from reporting of serious 
adverse events (discussed in Section 3.4.1) and information 
available on online drug user forums related to self-reported 
user experiences.
It should be noted that the specific substance(s) used in the 
self-reported experiences provided in this report cannot be 
confirmed; similarly it is also not possible to confirm the 
strength, purity, dose/amount, etc., used by those posting 
their experiences on said forums. In addition, the information 
provided on user websites and from specific user groups may 
(24) For comparison, reported mouse intraperitoneal LD50 values for fentanyl are 
26.3 mg/kg (Vuckovic et al., 2011) and 17.5 mg/kg (Gupta et al., 2013); mouse 
intravenous LD50 values of 238 and 2.91 mg/kg fentanyl, respectively (Gupta et 
al., 2013); mouse oral LD50 values of 470, 62 and 9.3 mg/kg for morphine and 
fentanyl and acetylfentanyl, respectively (Higashikawa and Suzuki, 2008b).
not necessarily be representative of other users of 
acryloylfentanyl and should be regarded as illustrative only.
Route of administration
Acryloylfentanyl may be taken orally (as powder in capsules or 
tablets); nasally (as a spray, a powder or tablets); and by 
injecting a solution of the substance.
Self-reports available on online forums describe snorting or 
inhalation by smoking or vaporising the ‘free base’ of 
acryloylfentanyl but this route has not been reported by any of 
the Member States. Since the free base is poorly soluble in 
water, injecting users dissolve the homemade solution of the 
citrate salt of the drug; ethanol has also been used as co-
solvent.
From the data reported to the EMCDDA, nasal sprays may be 
a common route of administration of acryloylfentanyl. These 
require that a solution of acryloylfentanyl is prepared either by 
the user directly or by the seller. It is unlikely that these 
solutions are prepared taking into account the effective and 
lethal dose for acryloylfentanyl, as these are not known from 
published studies. Moreover, the solutions themselves are 
prepared using small amounts of substance (for example 5 to 
20 mg of acryloylfentanyl in 10 mL) (25). Minor errors in dilution 
or weighing can therefore lead to significant variations in the 
concentration of acryloylfentanyl in solution, which can 
subsequently result in overdoses.
Settings of use
Data from serious adverse events reported to the EMCDDA 
suggests that acryloylfentanyl is used at home, with 20 (50%) 
out of 40 deaths having occurred in the decedents residence 
and a further 5 deaths occurring ‘in bed’.
Limited data from users forums is also suggestive of home 
setting, but many users claim they can go about their daily 
lives while under the influence, and dose intermittently during 
the day, (e.g. at work).
Dose, re-dosing, drug regimens
As with all psychoactive substances, the dose required to 
attain the desired effects depends on the route of 
administration. The available data, however, does not allow the 
identification of common/typical doses of acryloylfentanyl 
regardless of route.
There are no clinical studies on the doses required to produce 
subjective effects of acryloylfentanyl in humans. Limited data 
reported to the EMCDDA suggests that doses of 
(25) See for example: https://www.flashback.org/t2671134 or http://www.
bluelight.org/vb/threads/715710-Acrylfentanyl 
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acryloylfentanyl from 0.1 to 68 mg may be taken, administered 
orally or by nasal insufflation.
The time period in which these doses were taken was 
specified only in 2 cases. For these the route of administration 
was nasal. In one case the user was reported to have taken 20 
mg of acryloylfentanyl daily ‘for the last months’ and in the 
second case the user was said to have used 20 mg 
acryloylfentanyl/day at (or around) the time of the intoxication, 
and that prior to that ‘lower doses’ were used for ‘about 3 
months’. It is important to note that in both these cases the 
consumption of acryloylfentanyl was not confirmed 
analytically from biological samples taken from the users.
In one online forum, users described starting with a 50/50 
mixture of water/acryloylfentanyl and a dose of 2-3 sprays, 
after which they wait for the onset of effects. If nothing 
happens, users describe that they either spraying until 
a desired effect is reached. One user said he re-dosed with 
a couple of sprays every 2 hours or so during the day (26).
User self-reports posted on Internet forums also mention 
sub-milligram doses administered by nasal spray as being 
psychoactive.
The available data suggests that polydrug use might be 
common in those using acryloylfentanyl.
Subjective, psychological, and behavioural effects
There are no human clinical studies assessing the 
psychological and/or behavioural effects of acryloylfentanyl in 
humans. From limited data available in drug user websites, the 
psychoactivity of acryloylfentanyl is similar to that of other 
opioids and characterised by relaxation and euphoria.
Effect on ability to operate machinery and drive
Based on limited data from non-clinical studies, serious 
adverse events, and self-reported user experiences, it may be 
assumed that the acute behavioural effects of acryloylfentanyl 
on operating machinery and driving are similar to those 
caused by other opioid-type narcotic-analgesics.
Availability, supply, price
Online vendors
A structured search by the EMCDDA of online vendors (27) of 
acryloylfentanyl on the surface web (28) was conducted in 
(26) Source: https://www.flashback.org/t2671134 (accessed: 24 October 2016).
(27) This includes vendors that appear to be consumer-orientated as well as 
vendors, for example on B2B sites, which appear to be manufacturers and/or 
wholesalers. It excludes those selling acryloylfentanyl through online classified 
advertisements, social media, and user websites.
(28) The search of online vendors of acryloylfentanyl was performed on 
21/10/2016 using the search strings: ‘buy acryloylfentanyl’ (searches in English, 
Swedish and Danish, including variations in spelling). The first 100 results were 
October 2016. The search identified 9 vendors that appeared 
to be based in, and/or claim to have presence in China (n=6 
sites), in Hong Kong (n=1), in India (n=1 sites) and in Denmark 
(n=1). 8 of the sites presented information in English and 1 site 
in Danish. Three of the sites only provided prices for 
acryloylfentanyl on application, two presented prices as 
‘negotiable’ and one website displayed no information on 
price. In the latter, quantities from 10 gram to 1000 kg were on 
sale, packaged in foil bags, drums or bottles. The remaining 3 
sites listed quantities and prices. Briefly:
 ¡ on these sites acryloylfentanyl was typically sold as 
a ‘research chemical’;
 ¡ the minimum quantity offered was 1 mg (n=1 sites) with 
a price of EUR 2.70. Nonetheless the minimum order in this 
website is EUR 67;(29)
 ¡ the maximum quantity offered was 500 g (n=1 sites) with 
a price of EUR 7,322;
Prevalence of use
No data from general population surveys or targeted surveys 
were found on the prevalence of use of acryloylfentanyl.
Information on the use of acryloylfentanyl in Europe is mostly 
limited to discussions on user websites. From these 
discussions, it appears that acryloylfentanyl is used by 
psychonauts and users with experience of other opioids.
 3.5.  Information on whether or not the new 
substance is currently under assessment, or has 
been under assessment, by the UN system 
(Article 5.2(e) of the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 15 September 2016, the World Health Organization 
informed the EMCDDA that acryloylfentanyl is currently not 
under assessment and has not been under assessment by the 
UN system.
recorded and the sites reviewed. Each identified vendor site was then scored for 
information on warehouse location, quantities and prices, and substance 
marketing.
(29) Prices listed in DKK were converted to EUR according to Google exchange 
rate from the 25.10.2016 (DKK 1 = EUR 0,13). 
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 3.6.  The date of notification on the Reporting Form 
of the new psychoactive substance to the 
EMCDDA or to Europol (Article 5.2(f) of the 
Council Decision)
The first official EMCDDA–Europol notification of 
acryloylfentanyl dates from 7 July 2016 from the Danish 
National Focal Point. The Reporting Form details a capsule 
that was seized on 11 May 2016 by the Department of 
Forensic Psychiatry of the Aalborg Psychiatric Hospital. The 
identification and analytical characterisation was based on 
a range of analytical techniques GC-MS, high-resolution mass 
spectrometry (HR-MS) and NMR. The GC-MS analysis showed 
that the synthetic precursor used was N-phenyl-1-(2-
phenylethyl)piperidin-4-amine (4-ANPP) (30), which can also 
be used for the synthesis of fentanyl. An impurity, 
triethylamine hydrochloride, was also detected by NMR 
analysis (see section 3.8.1 for more detailed information).
Acryloylfentanyl was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System and a profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including public health alerts, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey, and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
It is important to note that acryloylfentanyl has been detected 
on the European market since at least April 2016, as 
evidenced by a seizure of the substance in liquid form 
reported by the Swedish National Focal Point in August 2016.
 3.7.  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Five Member States (Cyprus, Ireland, Latvia, Sweden and the 
United Kingdom) reported that acryloylfentanyl is controlled 
under drug control legislation.
 ¡ In Cyprus, acryloylfentanyl is controlled within the context 
of a generic clause which addresses fentanyl chemical 
groups.
 ¡ In Ireland, acryloylfentanyl is controlled under the Misuse 
of Drugs act 1977 (Schedule 1 (d) (iv), S.I. 251 of 1987) 
by way of a generic definition.
(30) 4-anilino-N-phenethylpiperidine.
 ¡ In Latvia, acryloylfentanyl is included in the Cabinet 
Regulation N 847 ‘Regulations regarding Narcotic 
Substances, Psychotropic Substances and Precursors to 
be Controlled in Latvia’ and the law ‘On the Procedures for 
the Coming into force and Application of the Criminal Law’.
 ¡ In Sweden, acryloylfentanyl has been regulated as 
a narcotic since the 16 August 2016.
 ¡ In the United Kingdom, acryloylfentanyl is controlled under 
the Misuse of Drugs Act 1971 by way of a generic definition.
Two Member States (Austria and Poland) reported that 
acryloylfentanyl is controlled under specific new psychoactive 
substances control legislation. In Austria, acryloylfentanyl may 
be covered by the Austrian Act on New Psychoactive 
substances due to the presence of a phenethylamine moiety 
in the structure of the substance (31). In Poland, 
acryloylfentanyl is controlled according to the general 
definition of the ‘substitute drug’ which has been included to 
the Act of 8 October 2010 amending the Act on counteracting 
drug addiction and the Act on State Sanitary Inspection 
(Journal of Laws ‘Dz.U.’ No. 213, item 1396). Article 44b of the 
above mentioned Act bans manufacturing or introducing 
substitute drugs to trade.
In Norway, the import of, trade in and marketing of 
acryloylfentanyl is controlled by the Medicines Act.
Twenty-one Member States (Belgium, Bulgaria, Croatia, Czech 
Republic, Denmark, Estonia, Finland (32), France, Germany, 
Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, 
Netherlands, Portugal, Romania, Slovakia, Slovenia, and 
Spain) and Turkey reported that acryloylfentanyl is not subject 
to control measures at the national level.
 3.8.  Further information (Article 5.2(h) of the Council 
Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, or 
Norway, about the chemical precursors or manufacturing 
methods used to make the acryloylfentanyl which has been 
detected within Europe.
(31) Austria reported that ‘Due to its phenetylamine structure acryloylfentanyl is 
unintentionally covered by the Austrian Act on New Psychoactive substances – 
but some experts might see it differently (https://www.ris.bka.gv.at/
GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnumm
er=20007605)’.
(32) Finland reported that the substance is proposed to be controlled as 
a narcotic; the scheduling is expected to come into force on 14 November 2016. 
15 / 24
JOINT REPORTS I Acryloylfentanyl
The synthesis of acryloylfentanyl has been described in the 
literature. The two published synthetic methods for 
acryloylfentanyl describe the acylation of the precursor 
4-ANPP (33,34), with acryloyl chloride (35) (Maryanoff et al., 
1982; Zhu et al., 1981) or 3-chloropropionyl chloride (36) 
(Essawi, 1999).
The detection of 4-ANPP in a seized sample of acryloylfentanyl 
in Denmark (section 3.6) and the availability of 4-ANPP on the 
chemicals market suggest its use as precursor in the 
manufacture of the acryloylfentanyl. In addition, the presence 
of triethylamine hydrochloride in the same sample indicates 
a possible modification of the Siegfried method, also used for 
the synthesis of fentanyl, using triethylamine as for the 
acetylation reaction instead of pyridine (Breindahl et al., 
2016).
The manufacture of acryloylfentanyl relies on precursors and 
synthetic methods similar to those used for the manufacture 
of pharmaceutical fentanyl (Casy and Huckstep, 1988; Gupta 
et al., 2013; Zee and Wang, 1980). Therefore the methods 
developed for the synthesis of fentanyl are applicable to 
acryloylfentanyl but use a different acylating agent in the final 
acylation step.
Most of the synthetic procedures are straightforward, use 
common laboratory equipment and precursors, and detailed 
recipes are available on the Internet (37). While only basic 
knowledge of synthetic chemistry is required, due to the 
potency of fentanyls caution is required when carrying out the 
final synthetic step as well as when purifying and handling the 
substance (38). Likewise, skin contact with or inhalation of 
fentanyls pose a serious health hazard. In addition to 
exercising extreme caution, the multiple doses of the opioid 
antagonist naloxone, as an antidote to poisoning in an 
accidental exposure, should be available when handling 
materials suspected to contain these substances (CDCP, 
2013; DEA, 2016).
(33) CAS RN: 21409-26-7. For analytical characterisation, see: http://www.
swgdrug.org/Monographs/4ANPP.pdf. Note that 1-(2-phenylethyl)piperidin-4-
one, or NPP (CAS RN: 39742-60-4), a precursor to 4-ANPP, is also used for the 
manufacture of the bronchodilatory medicine fenspiride.
(34) The synthesis of 4-ANPP from phenethylamine and ethyl (or methyl) acrylate 
is well documented (Beckett et al., 1959; Jończyk et al., 1978; Maryanoff et al., 
1982). For another route, see Valdez et al., 2014.
(35) IUPAC name: prop-2-enoyl chloride; CAS RN: 814-68-6; European Community 
(EC) Number: 212-399-0
(36) IUPAP Name: 3-chloropropanoyl chloride, CAS RN: 625-36-5; European 
Community (EC) Number: 210-890-4.
(37) The detailed description of the most common procedure, often called the 
‘Siegfried method’, is readily available on the Internet (see, for example, http://
opioids.com/fentanyl/synthesis.html).
(38) Self-educated clandestine chemists commented on the risk while discussing 
the synthesis of fentanyl and its potent 3-methyl and α-methyl homologues 
(comment was posted on 7 May, 2002); available at: https://the-hive.archive.
erowid.org/forum/showflat.pl?Cat=&Number=260275 (Accessed: 6 October 
2016).
The precursors N-phenethyl-4-piperidone (NPP) and 4-ANPP 
are offered from gram to bulk (multikilogram) quantities on the 
Internet from dozens of suppliers. For example, prices for the 
immediate precursor 4-ANPP range from USD 75 per 100 
gram to USD 5000 per 1 kg.
Acryloylfentanyl could be potentially used as a precursor to 
fentanyl by saturating the double bond of the acrylamide 
moiety using catalytic hydrogenation (Huckle et al., 1972).
None of the synthetic precursors mentioned in this section are 
included in Table I or Table II of the United Nations Convention 
against Traffic in Narcotic Drugs and Psychotropic 
Substances, 1988. In June 2010, the USA Drug Enforcement 
Administration placed 4-ANPP (named ANPP in the regulation) 
into Schedule II of the Controlled Substances Act (DoJ-DEA, 
2010).
In summary, the synthesis of acryloylfentanyl has been 
described in the literature. Other routes developed for the 
production of fentanyl may also be used for the manufacture 
of acryloylfentanyl. There is no information on the actual 
method(s) used for the production of acryloylfentanyl that has 
been detected in Europe to date.
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of acryloylfentanyl. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by any Member State that 
indicated that acryloylfentanyl had any other use apart from in 
analytical reference materials and scientific research.
From the available information, it does not appear that 
acryloylfentanyl is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a European Union 
database on the synthetic route of all medicinal products.
Fifteen countries (Austria, Croatia, Czech Republic, Denmark, 
Estonia, Finland, Greece, Hungary, Ireland, Malta, Netherlands, 
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Poland, Slovakia, Slovenia, and Spain) reported that 
acryloylfentanyl is not used to manufacture a medicinal 
product for human use. Eight countries (Belgium, Germany, 
Iceland, Italy, Norway, Portugal, Sweden, and the United 
Kingdom) reported that it was unknown if acryloylfentanyl is 
used to manufacture a medicinal product for human use.
Fifteen countries (Austria, Czech Republic, Denmark, Estonia, 
Finland, France, Greece, Ireland, Italy, Latvia, Malta, Poland, 
Slovakia, Spain, and the United Kingdom) provided information 
that acryloylfentanyl is not used to manufacture a medicinal 
product for veterinary use. Eight countries (Belgium, Germany, 
Iceland, Netherlands, Norway, Portugal, Slovenia, and 
Sweden) reported that it was unknown if acryloylfentanyl is 
used to manufacture a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if 
acryloylfentanyl is used in the manufacture of medicinal 
products for human or veterinary use and which are centrally 
authorised within the European Union.
  4.  Information from the EMA 
(Article 5.3 of the Council Decision)
 4.1.  Marketing authorization
Twenty-three countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Malta, Netherlands, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that acryloylfentanyl has not been 
granted a marketing authorization as a medicinal product for 
human use.
Twenty-three countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Iceland, 
Ireland, Italy, Latvia, Malta, Netherlands, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden and the United 
Kingdom) reported that acryloylfentanyl has not been granted 
a marketing authorization as a medicinal product for 
veterinary use.
The EMA also reported that acryloylfentanyl has not been 
granted a marketing authorization as a medicinal product for 
neither human nor veterinary use through the centralized 
procedure.
 4.2. Application for a marketing authorization
Twenty-three countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Malta, Netherlands, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that acryloylfentanyl is not the 
subject of an application for a marketing authorization as 
a medicinal product for human use.
Twenty-three countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Iceland, 
Ireland, Italy, Latvia, Malta, Netherlands, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden and the United 
Kingdom) reported that acryloylfentanyl is not the subject of 
an application for a marketing authorization as a medicinal 
product for veterinary use.
The EMA also reported that acryloylfentanyl is not the subject 
of an application for a marketing authorization for neither 
human nor veterinary use through the centralized procedure.
 4.3. Suspended marketing authorization
Twenty-three countries (Austria, Belgium, Croatia, Czech 
Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Iceland, Ireland, Italy, Malta, Netherlands, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that that there had been no cases 
of suspended marketing authorization in respect to 
acryloylfentanyl as a human medicine.
Twenty-three countries (Austria, Belgium, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Iceland, 
Ireland, Italy, Latvia, Malta, Netherlands, Norway, Poland, 
Portugal, Slovakia, Slovenia, Spain, Sweden and the United 
Kingdom) reported that that there had been no cases of 
suspended marketing authorization in respect to 
acryloylfentanyl as a veterinary medicine.
The EMA also reported that acryloylfentanyl is not the subject 
of a suspended marketing authorization for neither human nor 
veterinary use through the centralized procedure.
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I 5. Conclusion
Acryloylfentanyl is a synthetic opioid. It is closely related to 
fentanyl, which is controlled under the United Nations Single 
Convention on Narcotic Drugs of 1961. Data suggests that 
acryloylfentanyl is likely to be a potent opioid narcotic 
analgesic and may have an abuse liability and dependence 
potential in humans; these effects may be broadly comparable 
to fentanyl.
Acryloylfentanyl has been available in the European Union 
since at least April 2016 and has been detected in 6 Member 
States. In most cases it has been seized as a liquid, but other 
forms such as tablets, powders and a capsule have also been 
detected. The detected quantities are relatively small; 
however, they should be taken in the context of the high 
potency of the substance.
There is no indication of illicit production sites within the 
European Union. Acryloylfentanyl seems to be sourced as 
a powder from China (routing through Latvia on one occasion). 
The powders were reported to be used in the making of 
solutions, which are then placed in nasal spray containers. 
One country reported that two individuals linked to organised 
crime groups were involved in the illicit trade of 
acryloylfentanyl.
Acryloylfentanyl is sold as a ‘research chemical’ online and is 
available in small and wholesale amounts. Due to its close 
structural similarity to fentanyl, acryloylfentanyl can 
theoretically be used as a precursor for fentanyl.
42 deaths associated with acryloylfentanyl have been 
reported by 4 Member States, of which 40 were analytically 
confirmed. In 29 of these deaths acryloylfentanyl was the 
cause of death or contributed to the death. All deaths 
occurred in 2016; 80% of them occurred within a period of 
three months. One Member State reported 21 acute 
intoxications, 13 of which were life threatening and required 
hospitalisation. The acute intoxications were not analytically 
confirmed.
Information on the use of acryloylfentanyl in Europe is limited. 
It appears that acryloylfentanyl is used as a drug in its own 
right.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of acryloylfentanyl, and the 
involvement of organised crime and possible consequences of 
control measures, could be thoroughly assessed through 
a risk assessment procedure in accordance with Article 6 of 
Council Decision 2005/387/JHA.
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Country Image Description
Slovenia Collected sample, 10 May 2016
Light green powder
Collecting authority: National Forensic Laboratory – test purchase 
in the frame of EU co-funded project RESPONSE
Denmark Seizure, 11 May 2016
Capsule, seized in Aalborg
Seizing authority: Dept. of Forensic Psychiatry, Aalborg Psychiatric 
Hospital
Finland Seizure, 8 August 2016
Tablets, seized in Åland
Seizing authority: Police
I  Annex 1 Images from seizures and collected samples provided to the EMCDDA.
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I  Annex 2 Images provided to Europol. Samples of nasal spray bottles seized by Swedish authorities in different cases.
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